Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
Trial · NCT04852679
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Clinical Benefit Rate (CBR) of Tumour Response Assessed by Blinded Independent Central Review (BICR) at Week 24 | RECIST assessments performed at baseline (within 28 days before start of study intervention) and Weeks 24 | The ITT analysis set included all participants who received at least 1 dose of study intervention. | percentage of participants | NUMBER |
| SECONDARY | Progression Free Survival (PFS) by BICR Within Weeks 24 and 48 | RECIST assessments performed at baseline (within 28 days before start of study intervention) and Weeks 24 and 48 | The ITT analysis set included all participants who received at least 1 dose of study intervention. | weeks | MEDIAN |
| SECONDARY | Overall Survival (OS) at the End of the Main Intervention Period | RECIST assessments performed at baseline (within 28 days before start of study intervention) and Week 48 (end of the main intervention period) | The ITT analysis set included all participants who received at least 1 dose of study intervention. | weeks | MEDIAN |
| SECONDARY | Time to Progression (TTP) During Main Intervention Period | RECIST assessments performed at baseline (within 28 days before start of study intervention) and Weeks 12, 24, 36 and 48 | The ITT analysis set included all participants who received at least 1 dose of study intervention. | weeks | MEDIAN |
| SECONDARY | Percentage of Participants Alive and Without Tumour Progressive at Weeks 24 and 48 | RECIST assessments performed at baseline (within 28 days before start of study intervention) and Weeks 24 and 48 | The ITT analysis set included all participants who received at least 1 dose of study intervention. | percentage of participants | NUMBER |
| SECONDARY | Clinical Benefit Rate Assessed by BICR at Week 48 | RECIST assessments performed at baseline (within 28 days before start of study intervention) and Week 48 | The ITT analysis set included all participants who received at least 1 dose of study intervention. | percentage of participants | NUMBER |
| SECONDARY | Overall Response Rate (ORR) at Weeks 24 and 48 | RECIST assessments performed at baseline (within 28 days before start of study intervention) and Weeks 24 and 48 | The ITT analysis set included all participants who received at least 1 dose of study intervention. | percentage of participants | NUMBER |
| SECONDARY | Disease Control Rate (DCR) at Weeks 24 and 48 | RECIST assessments performed at baseline (within 28 days before start of study intervention) and Weeks 24 and 48 | The ITT analysis set included all participants who received at least 1 dose of study intervention. | percentage of participants | NUMBER |
| SECONDARY | Number of Participants With Neuroendocrine Tumours (NET)-Related Clinical Symptoms at Weeks 24 and 48 | Weeks 24 and 48 | The ITT analysis set included all participants who received at least 1 dose of study intervention. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline in Plasma Chromogranin A (CgA) at Weeks 12, 24, 36 and 48 | Baseline (within 28 days before start of study intervention) and Weeks 12, 24, 36 and 48 | The ITT analysis set included all participants who received at least 1 dose of study intervention. | microgram per liter | MEAN |
| SECONDARY | Change From Baseline in 5-Hydroxyindoleacetic Acid (5-HIAA) at Weeks 12, 24, 36 and 48 | Baseline (within 28 days before start of study intervention) and Weeks 12, 24, 36 and 48 | The ITT analysis set included all participants who received at least 1 dose of study intervention. | milligram per liter | MEAN |
| SECONDARY | Change From Baseline in Quality of Life (QoL) Assessment at Weeks 12, 24, 36 and 48 | Baseline (within 28 days before start of study intervention) and Weeks 12, 24, 36 and 48 | The ITT analysis set included all participants who received at least 1 dose of study intervention. | units on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04852679/outcomes